
Cardiomyopathy
Latest News
Latest Videos

Shorts




Podcasts
CME Content
More News

A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.
























































